7/18/25
Investing.com -- Leerink Partners upgraded Elanco Animal Health (NYSE:ELAN) to Outperform and downgraded Zoetis (NYSE:ZTS) to Market Perform on diverging growth prospects and shifting dynamics in the animal health market.
Elanco’s price target was raised to $18 from $14.50, with the brokerage pointing to strong early interest in its new U.S. pet health product Credelio Quattro, as well as growing momentum for Zenrelia.
Conversely, Zoetis’s target was cut to $155 from $180, with Leerink citing growing competition in legacy dermatology and parasiticide categories and a slowdown in momentum for Librela, a key new launch.
While Leerink still expects Zoetis to post revenue and earnings growth, it sees the pace decelerating as rivals like Elanco and Merck (NSE:PROR) gain share.
7/18/25
Investing.com -- Leerink Partners upgraded Elanco Animal Health (NYSE:ELAN) to Outperform and downgraded Zoetis (NYSE:ZTS) to Market Perform on diverging growth prospects and shifting dynamics in the animal health market.
Elanco’s price target was raised to $18 from $14.50, with the brokerage pointing to strong early interest in its new U.S. pet health product Credelio Quattro, as well as growing momentum for Zenrelia.
Conversely, Zoetis’s target was cut to $155 from $180, with Leerink citing growing competition in legacy dermatology and parasiticide categories and a slowdown in momentum for Librela, a key new launch.
While Leerink still expects Zoetis to post revenue and earnings growth, it sees the pace decelerating as rivals like Elanco and Merck (NSE:PROR) gain share.
投資の参考になりましたか？